Published April 23, 2024
Veeva Systems, IQVIA, & the Pharma Sales Flow
inpractise.com/articles/veeva-systems-iqvia-and-the-pharma-sales-flow
Executive Bio
Former VP, Global Accounts at Veeva Systems
Interview Transcript
Disclaimer: This interview is for informational purposes only and should not be relied upon as a basis for investment decisions. In Practise is an independent publisher and all opinions expressed by guests are solely their own opinions and do not reflect the opinion of In Practise.
This is a snippet of the transcript.to get full access.
How come they've done that though? Because I thought in the Veeva contract that they couldn't partner with someone who's a competitor or is did they only partner when Veeva announced they were going to shift off to Vault?
Yes, it's a good question. I don't know the ins and outs of the contract. It was interesting when Salesforce allowed OCE to build a couple of years back. That's the question. Maybe that was speculative, but maybe that's when Veeva thought, well, hey, if they're going to let someone else do it, it's our time to really push forward with the plan. So that could have been the case. I don't know how that one worked out because it was interesting. I was working there at that time. I was managing global accounts that we were competing against OCE. We almost lost one of them. They committed to OCE. OCE could not deliver, so they ended up having to stay with Veeva. But from a headspace or from a commitment perspective, we were told by this top 20 pharma, we're going to OCE.
Free Sample of 50+ Interviews
Sign up to test our content quality with a free sample of 50+ interviews.
Or contact sales for full access
Related Content

Medpace: CRO Customer Interactions
Former Clinical Trial Executive at Medpace

Braze: SMB vs Enterprise Dynamics
Current Braze Partner

Thryv: SMB Data Advantage & Keap-Driven Expansion
Former EVP at Vendasta

Gartner: Seat Strategy & Multi-Year Retention
Former Vice President of Sales Operations & Strategy at Gartner
© 2024 In Practise. All rights reserved. This material is for informational purposes only and should not be considered as investment advice.